(Q38877437)

7 September 2017

title

Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen (English)

1 reference

7 September 2017

Corinne R Ley

1

1 reference

7 September 2017

Nathan R Beattie

2

1 reference

7 September 2017

Shorouk Dannoon

3

1 reference

7 September 2017

Melanie Regan

4

1 reference

7 September 2017

Henry VanBrocklin

5

1 reference

7 September 2017

Clifford E Berkman

6

1 reference

7 September 2017

language of work or name

English

0 references

publication date

29 April 2015

1 reference

Bioorganic & Medicinal Chemistry Letters

7 September 2017

published in

1 reference

7 September 2017

volume

25

1 reference

7 September 2017

issue

12

1 reference

7 September 2017

page(s)

2536-2539

1 reference

Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography

7 September 2017

cites work

1 reference

12 December 2020

A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?

1 reference

12 December 2020

Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM).

1 reference

12 December 2020

Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids

1 reference

12 December 2020

Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase

1 reference

12 December 2020

Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.

1 reference

12 December 2020

PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

1 reference

12 December 2020

Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates

1 reference

12 December 2020

Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate

1 reference

12 December 2020

(90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy

1 reference

12 December 2020

Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway.

1 reference

12 December 2020

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors

1 reference

12 December 2020

High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen

1 reference

12 December 2020

Microfluidic system for studying the interaction of nanoparticles and microparticles with cells

1 reference

12 December 2020

Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes

1 reference

12 December 2020

In vivo cancer targeting and imaging with semiconductor quantum dots

1 reference

12 December 2020

11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase).

1 reference

12 December 2020

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression

1 reference

12 December 2020

Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor

1 reference

12 December 2020

A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent.

1 reference

12 December 2020

Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen

1 reference

12 December 2020

Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.

1 reference

12 December 2020

Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy

1 reference

12 December 2020

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer

1 reference

12 December 2020

Expression of the prostate-specific membrane antigen

1 reference

12 December 2020

Synthesis and Biological Evaluation of Thiol-Based Inhibitors of Glutamate Carboxypeptidase II: Discovery of an Orally Active GCP II Inhibitor

1 reference

12 December 2020

Progress in the discovery and development of glutamate carboxypeptidase II inhibitors

1 reference

12 December 2020

Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer

1 reference

12 December 2020

The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen

1 reference

12 December 2020

Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption

1 reference

12 December 2020

A targeted low molecular weight near-infrared fluorescent probe for prostate cancer

1 reference

12 December 2020

Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics

1 reference

12 December 2020

10.1016/J.BMCL.2015.04.047

Identifiers

DOI

1 reference

7 September 2017

0 references

1 reference